Study details
Enrolling now
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
Massachusetts General Hospital
NCT IDNCT07236190ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
40
Study length
about 1.5 years
Ages
55+
Locations
1 site in MA
What this study is about
Researchers are testing a treatment called NPC1 to see if it affects biomarkers related to Alzheimer's disease in adults with signs of the disease. The trial will last 546 days and involve approximately 40 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take NPC1
- 2.Take NPC1-Placebo/Control
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Safety and Tolerability of NPC1
Body systems
Neurology